SacriX SI Joint Fusion: Procedure, Evidence & Recovery
SacriX SI joint fusion uses implanted fixation devices to stabilize the sacroiliac joint and support bone fusion in selected patients. It is one option within minimally invasive SI-joint fusion, not a treatment for every cause of low-back or buttock pain.
This page explains the SacriX implant and approach. For general fusion candidacy, diagnostic injection thresholds, RFA versus fusion and the broader recovery pathway, read our SI-joint fusion guide.
At SpinePain Solutions, Dr. Amit Sharma currently performs most appropriate SI-joint fusion procedures using SacriX. Posterior LinQ remains an option for selected patients. This practice pattern does not establish that either device is universally superior.
What Is the SacriX Implant System?
FDA documentation describes titanium-alloy solid and fenestrated screw options with a cannulated core that can accommodate bone graft. Implant size and configuration are selected for the planned operation. The intent is initial mechanical stabilization while fusion develops; placing an implant does not mean that biological fusion is already complete.
SacriX is described in published technique reports as using an image-guided percutaneous lateral-oblique transfixing approach. Current manufacturer terminology also includes a posterolateral-medial-oblique approach. These names describe the surgical corridor; they should not be confused with a posterior intra-articular allograft technique such as LinQ. Ask which exact implant and trajectory are planned for your procedure.
FDA-Cleared, Not a Guarantee of Success
The accurate regulatory term is FDA-cleared. The system’s 510(k) documentation identifies its intended use for SI-joint fusion for conditions including joint disruptions and degenerative sacroiliitis. Clearance is not proof of superiority over another treatment and does not establish insurance coverage or predict your result. Review the FDA documentation.
Why Might SacriX Be Selected?
Once fusion candidacy has been evaluated, approach selection considers the available bony corridor, sacral anatomy, bone quality, previous pelvic or spine surgery, existing implants, graft strategy and procedural risk. A favorable injection alone does not establish that SacriX is the best approach.
- Anatomy: the proposed implant path must fit the patient’s pelvis and sacrum.
- Bone quality: osteoporosis or impaired bone healing requires assessment; a laboratory fixation result does not make a device automatically ideal for weak bone.
- Previous procedures: existing hardware and scar tissue can change the plan.
- Clinical goals: meaningful improvement in function is more realistic than a promise to eliminate every source of pain.
- Recovery feasibility: mobility, home support and the ability to follow restrictions matter.
For the complete diagnostic evaluation, see SI-joint dysfunction and SI-joint injection interpretation. Coverage requirements and injection thresholds must be checked for the actual plan and procedure.
How the SacriX Procedure Is Performed
- Planning: the team reviews anatomy, prior implants, medical risk, medication instructions and the proposed implant configuration.
- Positioning and anesthesia: the patient is positioned for image-guided access. The anesthesia plan is individualized.
- Image-guided access: fluoroscopic views, or additional imaging when appropriate, are used to plan and monitor the bony trajectory.
- Implant placement: the selected implant or implants are advanced across the joint according to the system’s technique. Bone graft is used as appropriate to the plan.
- Position assessment and closure: imaging assesses placement, the incision is closed and safe discharge is evaluated.
Many procedures are outpatient, but discharge depends on pain control, medical status and safe mobility. Procedure duration and incision size vary; neither should be presented as a universal promise.
Why Imaging and Trajectory Planning Matter
The sacrum contains nerve pathways, and implant position must respect the available bone and surrounding structures. Imaging is used throughout placement, not just at the end. An unusual sacral shape, weak bone or existing implants may require a modified plan. Guidance improves the ability to assess placement but does not eliminate malposition or neurological risk.
What Does the SacriX Evidence Actually Show?
The evidence includes different study designs and implant configurations. A technical report, laboratory comparison and randomized supervision study answer different questions; none should be converted into a universal patient success rate.
| Evidence type | Useful information | Important limitation |
|---|---|---|
| 2021 small pilot report | Describes lateral-oblique technique, clinical follow-up and CT findings | A small uncontrolled series cannot establish comparative effectiveness |
| 2025 biomechanical study | Compares implant pullout strength under laboratory conditions | Laboratory strength is not a patient pain-relief, fusion or complication outcome |
| 2023 salvage case report | Describes a lateral-oblique revision strategy in three cases | Does not establish reliable success across failed fusion presentations |
| 2025 randomized safety and competency study | Evaluates procedural supervision and safety in trained interventional pain physicians | Not a comparison of SacriX pain relief against LinQ, RFA or sham surgery |
Published SacriX-related studies may involve a different implant configuration or adjunct graft from your planned procedure. Evidence from other SI-fusion systems cannot be assigned automatically to SacriX. Ask which study applies to the exact technique being proposed.
The broader SI-fusion literature includes positive comparisons with nonsurgical care and a 2024 sham-controlled trial that did not demonstrate superiority at six months. That trial was not a SacriX-specific comparison. It informs balanced counseling about fusion overall, not a direct conclusion about this system. See the parent guide’s evidence discussion.
Can SacriX Be Used After a Previous SI-Joint Fusion?
A published three-case report describes salvage of failed direct lateral fixation using a lateral-oblique transfixation technique. This is an option to evaluate, not an assurance that existing implants can always be left in place or that another implant will restore relief.
Persistent pain first requires assessment for nonunion, implant loosening or malposition, infection, and competing lumbar or hip sources. Additional imaging and specialist review may be needed. Revision planning depends on the available anatomy and existing hardware. Read the salvage case report.
Recovery After SacriX SI Joint Fusion
The patient should receive written instructions for wound care, walking, weight bearing, assistive devices, medication, follow-up and work restrictions. Early walking does not necessarily mean unrestricted loading or exercise is safe.
- Use a walker or crutches if prescribed and follow the exact weight-bearing plan.
- Keep the incision protected and follow individualized showering instructions.
- Limit lifting, bending, twisting and exercise as directed.
- Begin rehabilitation only according to the operating clinician’s protocol.
- Drive only when cleared, free of impairing medication and able to brake and move safely.
- Expect return-to-work decisions to depend on commuting, sitting tolerance and physical job demands.
Incision comfort can improve before fusion develops. Bone healing continues over months, and persistent or recurrent symptoms require reassessment rather than an assumption of either success or failure. Read the SI-fusion recovery framework for the general timeline.
Risks and Alternatives
Potential risks include infection, bleeding or hematoma, nerve irritation or injury, implant malposition, loosening or migration, fracture, persistent or worsening pain, nonunion, anesthesia complications and revision surgery. Small incisions do not eliminate internal surgical risk.
Alternatives may include rehabilitation, medication management, therapeutic SI-joint injection, appropriately selected sacral lateral-branch RFA, posterior LinQ or another fusion approach, and treatment of a different pain generator. The SI-fusion parent page explains why RFA, injections and fusion have different anatomical targets and selection pathways.
Contact the treating team promptly for fever, drainage, spreading redness, increasing swelling or severe escalating pain. New major weakness, saddle numbness, bowel or bladder dysfunction, chest pain or shortness of breath require urgent medical evaluation.
SacriX Frequently Asked Questions
What is SacriX SI joint fusion?
SacriX is an implant system used to stabilize the sacroiliac joint and support fusion in selected patients. It uses titanium-alloy implants placed across the joint through an image-guided percutaneous approach. The planned implant configuration and technique depend on the patient’s anatomy and the specific system.
Is SacriX FDA-approved?
The more accurate term is FDA-cleared. FDA 510(k) documentation identifies the SacriX system as intended for SI-joint fusion for conditions including SI-joint disruptions and degenerative sacroiliitis. Clearance does not establish that it is superior to other treatments or guarantee an individual outcome.
Is SacriX better than posterior LinQ fusion?
Neither system is proven best for every patient. SacriX uses implants that cross the SI joint, while posterior LinQ uses a structural allograft placed through a different joint corridor. Anatomy, diagnosis, bone quality, prior implants, procedural risk and evidence for the exact system should guide the choice.
How long is recovery after SacriX SI joint fusion?
Recovery is individualized. Walking may begin early with appropriate assistance, but weight-bearing limits, lifting restrictions and rehabilitation depend on the operation and patient. Wound comfort can improve before biological fusion is complete. Do not assume that unrestricted activity is safe within days.
Can SacriX be used after a previous SI-joint fusion?
Sometimes it may be considered in a carefully evaluated revision case. Persistent pain after fusion requires assessment for nonunion, implant problems, infection and competing lumbar or hip causes. Published small case reports describe a lateral-oblique salvage approach, but they do not establish that it will work for every failed fusion.
Is SacriX covered by insurance?
Coverage is not automatic. It depends on the insurer, current policy, proposed fusion approach, diagnostic documentation and authorization requirements. The office should verify coverage for the planned procedure; FDA clearance alone does not establish insurance eligibility.
What should I ask before choosing SacriX?
Ask why the SI joint is considered the pain source, why this approach fits your anatomy, which implant and graft are planned, what evidence applies to that configuration, what risks and alternatives matter, and what weight-bearing and work restrictions you will receive. Also ask what happens if pain persists or fusion does not develop.
Selected References
- U.S. Food and Drug Administration. SacriX Sacroiliac Joint Fusion Device System, K232605. Cleared September 28, 2023. Read the clearance and device description.
- Chin KR, et al. CT Scan and Clinical Outcomes of Novel Lateral-Oblique Percutaneous Sacroiliac Joint Fixation: Technique and Literature Review. 2021. Read the pilot report.
- Comparative biomechanical study assessing pullout strength of two SI-joint fixation implant designs. 2025. Read the laboratory study.
- Chin KR, et al. Salvage of failed direct lateral sacroiliac joint fixation using a new percutaneous lateral-oblique transfixation technique with two variable-threaded screws: a multicenter case report of three cases. 2023. Read the salvage report.
- Chin KR, et al. A prospective multicenter randomized controlled trial on safety and procedural competency in SI-joint fusion performed by interventional pain physicians trained by a spine surgeon. 2025. Read the safety and competency study.
- McCormick ZL, et al. Consensus practice guidelines on sacroiliac joint complex pain. 2025. Read the multispecialty guideline.
- Randers EM, et al. The effect of minimally invasive SI-joint fusion compared with sham operation: a double-blind randomized placebo-controlled trial. 2024. Read the sham-controlled trial.
- SacriX. Manufacturer description of the transfixation approach. Accessed September 17, 2026. View manufacturer information. Manufacturer material describes the system and is not independent comparative clinical evidence.
Dr. Amit Sharma & our minimally invasive pain & spine team.
